Fudan-Zhangjiang Bio-Pharma all set for Star board dual-listing

Science_testing_230x150
By Jonathan Breen
06 Apr 2020

Hong Kong-listed Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has won approval from Shanghai’s bourse to list shares on the Star board.

It has received the go ahead from the Shanghai Stock Exchange (SSE) to float on its Science and Technology Innovation Market (Star) — a Nasdaq-style board for new economy firms, the company said on Monday.

Fudan-Zhangjiang is not alone in aiming for a Star dual-listing. Last week, HKEX-traded ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.